



Rapid Setup of E-Submission Gateways for Regulatory Safety Reporting
Pharma Sponsors and Marketing Authorization Holders have the important responsibility of complying with global regulatory requirements by timely submitting all reported adverse events within the mandated timeframe to account for safety profile and the risk-benefit ratio of medicinal products. This requires companies to establish validated electronic submission gateways that facilitates transmission of IND Safety Reports, ICSRs, etc. directly from the safety database to different regulatory bodies in the E2B R2/R3 XML format.
At Techsol, we specialize in setting up Oracle Argus Interchange, an electronic submission and exchange module that enables the transmission of required ICH:E2B reporting functionality as well as the exchange of vital drug safety information with regulators and partners worldwide. Cases are reported instantly and accurately using standardized, worldwide reporting and transmission processes.
Our Safety Gateway Management Capabilities
- 15+ years of experience with Partner and Regulatory E-Submission Gateways
- Readily available Axway B2B and Oracle E2B gateway validation accelerators
- We have setup 70+ gateways to FDA, EU, PMDA, Health Canada etc.
- Extensive technical and functional domain expertise to manage gateways
- Our Safety Service Desk provides expert support for gateway change management
- Clients choose us as their extended safety technology services partner

Services We Offer
Our safety technical team has the expertise to setup electronic gateways from the Oracle Argus Safety Database to:
- United States: FDA’s Adverse Event Reporting System (FAERS) and the Individual Case Safety Report (ICSR) Portal
- European Union: European Medicines Agency’s Eudravigilance Medicinal Product Dictionary (EVMPD) and Electronic Reporting of Suspected Adverse Reactions (E2B) Gateway
- Japan: Pharmaceuticals and Medical Devices Agency’s (PMDA) ICSR Information Management System (IMS)
- Canada: Health Canada’s Electronic Adverse Reaction Reporting System (EARRS)
- Australia: Therapeutic Goods Administration’s (TGA) Adverse Drug Reactions System (ADRS)
- Switzerland: Swissmedic B2B gateway
Activities We Perform
> E-Submission Gateway implementation, configuration, and validation
> Configure Argus Interchange Service by updating the initialization (INI) file
> Validate generation of E2B XML files to ensure error-free XML submissions
> Complete Report Generation Validations
> Pilot testing completion with supporting documentation
> Troubleshooting failures and resolving reported incidents of gateways failures

Our Full Portfolio of Technology Services
End-to-End Pharmacovigilance Solutions
Pharmacovigilance Technology Solutions
Leverage our 15+ years of comprehensive experience and our portfolio of System Integration (SI) and Managed Cloud Services to enhance regulatory compliance in pharmacovigilance.
Pharmacovigilance Operations Oversight & Agentic AI Solutions
Manual oversight is often inefficient and error-prone, leading to compliance risks. As a result, there is a growing need for a digital, automated PV oversight framework to enhance efficiency, data quality, and real-time regulatory compliance
Operations Oversight & Agentic AI Platform – Compier PV Ops
Unique SaaS platform that co-exist with drug safety databases enable companies to proactively manage and automate global Pharmacovigilance compliance operations.
Integrated & Automated Functional Services
Life sciences organizations need a modern delivery framework that is purpose-built for agility, scalability, and compliance to efficiently address all of the regulatory obligations towards Pharmacovigilance.
TOTALVigilance - Functional Services
Simplify End-to-End Pharmacovigilance Compliance Obligations by combining People, Process, Technology, Automation & Quality.
Latest Relevant Case Studies

December 29, 2022
Establishing an Integrated Global Drug Safety and Signal Management Cloud Solution

December 29, 2022
Argus Safety Cloud Implementation and Validation on Oracle Cloud for HUGEL Pharma

December 29, 2022
Serious Adverse Event (SAE) Management, Review and Reporting to DCGI during the COVID 19 Pandemic for an Ophthalmology Clinical Study
Latest Relevant Insights

August 30, 2021
Literature Screening – Process overview, challenges en-route and the scope for automation